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Platelet vasopressin receptors in patients with congenital nephrogenic
diabetes insipidus. Arginine-vasopressin (AVP), interacts with at least
two types of receptors: V1 receptors which mediate the aggregating
effects of AVP on human blood platelets and other AVP actions on
vascular smooth muscle and hepatocytes; and V2 receptors which
mediate the antidiuretic effects on renal tubules. Congenital nephro-
genic diabetes insipidus (CNDI) is a rare X-linked disorder in humans
with abnormal renal and extrarenal V2-receptor responses. However,
the V1 receptor responses are apparently normal, since in these patients
blood pressure increases in response to AVP. To assess V1 receptor
responses, binding studies (3H-AVP) were done on intact platelets
obtained from 6 male patients with CNDI, 10 normal subjects and 4
patients with autosomal dominant central diabetes insipidus (ADCDI).
The affinity constant (0.68 0.04 vs. 0.59 0.06 nM) and the number
of specific binding sites per platelet (101 6 vs. 86 12) were similar
in the normal subjects and the patients with CNDI. However, the
number of binding sites per platelet was increased in the patients with
ADCDI (189 12). Platelet aggregation induced by AVP was equiva-
lent in the three groups. Platelet-fraction AVP was elevated in patients
with CNDI and undetectable in patients with ADCDI. These results
suggest that the structure and the function of V1 platelet receptor-
effector pathway are normal in patients with CNDI.
Vasopressin is thought to act on at least two distinct types of
receptors [1]. The V1 (platelet/vascular/hepatic) type is cyclase-
independent and is linked to the hydrolysis of phosphatidyl
inositol. The V2 (renal) receptor is linked to adenylate cyclase,
is phosphatidyl inositol independent and mediates renal water
reabsorption. Extrarenal vasopressin V2-like receptors seem to
be responsible for the vasodilating and coagulation stimulating
properties of vasopressin [2—61.
A better understanding of the interaction between vasopres-
sin and its receptors may be obtained through the study of
congenital nephrogenic diabetes insipidus and central autoso-
mal dominant diabetes insipidus, both rare hereditary human
diseases. In the first, a rare X-linked disorder, renal V2 receptor
responses are abnormal since, in affected male patients, an
antidiuretic response to the administration of either arginine-
vasopressin or the selective antidiuretic agonist l-desamino[8-
D-arginine]vasopressin (dDAVP) is not obtained [7, 8]. Extra-
renal V2 receptor responses are also abnormal since arterial
blood pressure did not decrease and plasma renin activity and
the release of coagulation factors, factor Vilic and von Wille-
brand factor, did not increase in response to the administration
of dDAVP [4, 51. However, arginine-vasopressin administration
increases arterial blood pressure, induces skin blanching and
abdominal cramps and stimulates the production of prostaglan-
din E2 in male patients [9—12], providing indirect evidence that
the V1 receptors are functional in these patients. These indirect
observations on V1 receptor responses were anecdotal and, in
general, involved the study of one male patient each by the
same investigator.
In the second hereditary disorder, namely, hereditary central
diabetes insipidus, V1 and V2 responses are apparently normal,
but the plasma concentration of arginine-vasopressin is low or
undetectable. This disorder is transmitted through an autosomal
dominant pattern [13].
The aim of the present studies was to provide direct proof of
the functionality of V1 receptor responses in patients with
congenital nephrogenic diabetes insipidus. Platelet vasopressin
receptors and vasopressin-induced platelet aggregation were
studied in normal subjects, in patients with congenital nephro-
genic diabetes insipidus and in patients with autosomal domi-
nant central diabetes insipidus, because arginine-vasopressin
(AVP) induces platelet aggregation in humans by activating the
V1 receptors. Previous studies in our laboratory [14] suggested
that arginine-vasopressin immunoreactivity in platelet-rich
plasma, designated "platelet-fraction arginine-vasopressin"
(platelet-AVP), could be used to estimate vasopressin binding
to specific platelet receptors, we therefore measured platelet-
AVP in the same three groups.
Our studies were designed to answer the following questions:
1) is platelet vasopressin receptor function normal in patients
with congenital nephrogenic diabetes insipidus? 2) are the
number of platelet vasopressin receptors and the platelet-
aggregation patterns induced by AVP regulated by plasma
concentrations of AVP? and 3) could platelet-AVP measure-
ments be used to differentiate central from nephrogenic diabe-
tes insipidus?
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Study subjects
A group of 14 male patients with congenital nephrogenic
diabetes insipidus (6 to 45 years old, mean age 23.6 3 years)
was recruited from eight different families. All had documented
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lifelong histories of polyuria and polydipsia, normal or elevated
plasma concentrations of arginine-vasopressin, and unconcen-
trated urine despite the administration of arginine-vasopressin
or dDAVP. In these patients, arterial blood pressure did not
decrease and plasma renin activity and the release of coagula-
tion factors, factor Yule and von Willebrand factor, did not
increase in response to the administration of dDAVP. All the
patients had family histories pathognomonic of an X-linked
mode of inheritance and had participated in two previous
studies reported by our laboratory [4, 5]. Two patients were not
receiving medication. The other patients discontinued their
hydrochiorothiazide treatment three days before sampling. No
other medications were allowed.
The second group consisted of eight women and two men (17
to 56 years old, mean age 34 5 years) from three different
families, with autosomal dominant central diabetes insipidus.
During dehydration and the infusion of hypertonic saline, they
were all characterized by dilute urine and undetectable concen-
trations of plasma arginine-vasopressin. Neither associated
hypothalamic insufficiency nor circulating antibodies against
arginine-vasopressin were observed. Renal function was nor-
mal and intranasal dDAVP treatment was successful.
The third group contained 10 normal subjects, five women
and five men (22 to 47 years old, mean age 37.6 2.5 years).
They denied taking any drug for the preceding two weeks.
Binding studies of 1H]AVP on intact human platelets
Studies of [3H]AVP binding on intact human platelets ob-
tained from six male patients (7 studies) with congenital neph-
rogenic diabetes insipidus, four patients (6 studies) with auto-
somal-dominant central diabetes insipidus and 10 normal
subjects (5 males, 20 studies; 5 females, 8 studies) were done as
previously described [14]. Venous blood (50 to 100 ml) was
collected in a citrate-phosphate-dextrose-adenine solution, and
the binding experiments were done the same day. A minimum
of ten concentrations of tritiated (40 Ci/mM, New England
Nuclear, Boston, Massachusetts, USA) vasopressin were used.
The methods of Scatchard [15] and Atkinson [161 were used to
analyze the results which were expressed either as femtomoles
of bound [3H]AVP or the number of binding sites, assuming
one binding per site. Studies of dose-dependent inhibition of
[3HIAVP binding by unlabelled AVP (Ferring) were also done
with Ki and [H50] being calculated as previously described [14].
Twenty-eight binding studies were done in 10 normal subjects
over a five year period. One normal subject (subject 1) was
studied 11 times, another (subject 2) four times and four other
normal subjects two times. The following coefficients of varia-
tion (standard deviation divided by mean value) were calculated
for subject 1: specific binding 30.2%, Kd (28.5%), Bmax (24.0%),
Hill number (13.2%), Kd Hill (27.0%), Ki (20.4%), Kd/Ki
(6.7%); for subject 2: specific binding (30.4%), Kd (29.0%),
Bmax (27.0%), Hill number (9.7%), Kd Hill (31.3%), Ki (32%),
Kd/Ki (14.1%). The variations observed in the four other
normal subjects during two studies were within the variations
calculated above.
Platelet aggregation measurements
Five patients (6 studies) with congenital nephrogenic diabetes
insipidus, four patients with autosomal central diabetes insipi-
dus and six normal subjects were studied. Venous blood (50 to
75 ml) was drawn on 0.01% heparin (1,000 IU/ml). Platelet-rich
plasma was prepared and platelet aggregation was measured at
37°C with a Bio-/Data Platelet Aggregation Profiler (Model
PAP-2A, Bio/Data Corporation, Willow Grove, Pennsylvania,
USA). The maximal change in light transmittance after the
addition of AVP was determined (Max). In studies on the
antagonism of the action of AVP by the specific vascular
antagonist [/3-mercapto-/3,/3,cyclopentamethyknepropionyl,-O-
Me,Tyr2,Arg8]vasopressin, the platelets were incubated with
the antagonist for 30 seconds before the addition of AVP. A
minimum of 10 concentrations of AVP and four concentrations
of antagonist were used. AVP was obtained from Ferring
(Malmo, Sweden) and the AVP vascular antagonist from Sigma
Chemical Co. (St. Louis, Missouri, USA).
Plasma and platelet-arginine-vasopressin measurements
These measurements were done as previously described [14]
in 12 patients with congenital nephrogenic diabetes insipidus, 10
patients with autosomal-dominant central diabetes insipidus
and 10 normal subjects (29 studies), all of whom had unlimited
access to water. In brief, two blood samples (A and B) of 5 ml
each were drawn in chilled EDTA-containing tubes after a 20
minute rest. Sample A was centrifuged at 4°C, 110 g for 20
minutes, and the platelet content of 100 d of the plasma was
determined (Coulter Counter). A 1 ml plasma sample was
frozen at —20°C, and within three weeks it was extracted with
acetone-petrol-ether and analyzed for AVP [14]. One hundred
plasma samples were obtained during these studies and their
platelet content was close to 300,000/1d. The plasma vasopres-
sin concentration was called "platelet-rich" plasma vasopres-
sin fraction. Sample B was centrifuged at 4°C, 950 g for 20
minutes. The one hundred plasma samples obtained during the
B series contained less than 30,000 plateletsfpi. The platelet-
rich vasopressin fraction minus the platelet-poor vasopressin
fraction was called platelet-AVP.
AVP concentrations were measured by radioimmunoassay as
previously described [17] with a sensitivity of 0.1 pg per tube
and a 50% displacement of the tracer obtained for 1.2 pg/tube.
The antiserum used (AS2849) did not cross react with dDAVP.
Plasma and platelet arginine-vasopressin measurements
during dehydration and hypertonic saline infusion in patients
with congenital nephrogenic diabetes insipidus and in
patients with autosomal-dominant central diabetes insipidus
Three male patients with congenital nephrogenic diabetes
insipidus were dehydrated for 8 to 10 hours and seven patients
with autosomal-dominant central diabetes insipidus were dehy-
drated for 12 to 16 hours. A 1 mI/kg body weight 3% saline
infusion was administered during the last two hours of dehy-
dration. Blood samples were obtained during the last four hours
of dehydration (including the period of hypertonic saline infu-
sion) at 0, 60, 120, 180, 210 and 240 minutes for plasma sodium,
osmolality, plasma arginine-vasopressin and platelet-fraction
arginine-vasopressin determinations. Urine samples were ob-
tained at the same time intervals for measurements of urinary
osmolality.
Statistical analysis
The results obtained in the three groups of subjects were
compared by variance and Newman-Keuls analyses [18]. Re-
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Table 1. [3HJAVP binding on intact platelets and dose-dependent inhibition of [3H]AVP binding by unlabeled AVP
Maximal concentration Kd KGroups Specific binding of binding sites per Bmax
number of studies % platelet fmol/mg protein nM
Normal subjects" (N = 27) 3.34 0.23 101 6 89.6 6.2 0.68 0.04 0.51 0.03
Patients with congenital 2.98 0.29 86 12 73.6 5.4 0.59 0.06 0.50 0.03
nephrogenic diabetes
insipidus (N = 7)
Patients with autosomal 6.72 0.59a 189 I2 122.9 94a 0.54 0.03 0.41 0.02
dominant central diabetes
insipidus (N = 6)
Kd is the equilibrium dissociation constant for [3H]AVP binding determined from saturation experiments. Scatchard analysis and Hill analysis
of the binding data led to similar Kd values. Hill number was close to I in the three groups of subjects suggesting the absence of any cooperativity.
Ki is determined from IC50 values for inhibition of [3HJAVP binding by unlabeled AVP.
a Significantly different from the other two groups by ANOVA followed by a Newman-Keuls test
b No differences were seen between male and female normal subjects
peated measurements in the same group of subjects were
compared with baseline values according to the method of
Dunnett [19]. A P value less than 0.05 was considered to be
statistically significant. Results are expressed as the mean SE.
Protocol approval and consent
All studies were approved by our institutional ethical review
committee. All participants in the study gave written informed
consent.
Results
Binding studies and plasma arginine-vasopressin
concentrations
Plasma AVP concentrations and the characteristics of
{3H]AVP platelet binding were similar in normal subjects and
patients with congenital nephrogenic diabetes insipidus (Table
1). Identical binding patterns were obtained in normal male and
female subjects (Kd = 0.7 0.04 vs. 0.64 0.08 nM; BMaX: 89.4
7.3 vs. 97.3 11.2 nM; maximal concentration of binding
sites per platelet: 96.8 4.9 vs. 109.7 18.0). However, in
patients with autosomal-dominant central diabetes insipidus
(DI) the specific binding characteristics (6.72 0.59%) and the
number of vasopressin receptors per platelet (189 12) were
almost double those found in the other two groups. Further-
more, their AVP plasma concentrations were undetectable
(<0.5 pg/mi). The affinity constant (Kd) values were similar in
the three groups and a Hill analysis gave similar Kd results. The
dose-dependent inhibition of [3H]AVP binding by unlabelled
AVP gave inhibition constant (Ki) values close to the Kd values
previously calculated.
Platelet aggregation by vasopressin
Platelet aggregation induced by increasing concentrations of
AVP (Fig. 1) and its inhibition by the specific vascular antago-
nist [/3-mercapto-,/3,cyclopentamethylenepropionyl,-O-Me,
Tyr2,Arg8}vasopressin (Fig. 2) were equivalent in the three
groups of subjects. Large variations in aggregation patterns
were seen in patients with congenital nephrogenic diabetes, and
large overlapping EC50 values were calculated: normal sub-
jects, 55.4 4.0 nM; congenital nephrogenic DI, 39.4 19.3
nM; autosomal-dominant central DI, 20.0 5.2 nM). As a
consequence, no statistically significant difference in aggrega-
tion patterns could be calculated among the three groups.
Platelet-fraction arginine-vasopressin measurements with ad
libitum water intake
Platelet-fraction arginine-vasopressin was undetectable (<0.5
pg/mi) in patients with autosomal central diabetes insipidus and
significantly different from the platelet-fraction arginine-vaso-
pressin values obtained in the other two groups (9.8 1.75
pg/mi in normal subjects and 14.8 5.0 pg/mI in patients with
congenital nephrogenic diabetes insipidus; Fig. 3). In contrast,
there was no significant difference between plasma arginine-
vasopressin concentrations in normal subject (1.23 0.18
pg/mi) and in patients with central diabetes insipidus (0.5 0
pg/mi, undetectable; Fig. 3).
Platelet-fraction arginine-vasopressin measurements during
dehydration and hypertonic saline infusion
Comparable degrees of dehydration, as judged by plasma
sodium concentrations, were obtained in patients with central
diabetes insipidus (maximum 152.7 0.9 mmol/liter) and in
patients with congenital nephrogenic diabetes insipidus (maxi-
mum 154.1 0.9 mmol/iiter; Fig. 4). Urinary osmolaiity re-
mained less than 250 mmoi/kg in both groups despite these
markedly elevated plasma sodium concentrations. Plasma con-
centrations of arginine-vasopressin were undetectable in pa-
tients with central diabetes insipidus. Plasma concentrations of
arginine-vasopressin responded normally to hyperosmolality in
patients with congenital nephrogenic diabetes insipidus (from
3.0 1.7 to 15.7 3.0 pg/mI). Platelet-fraction arginine-
vasopressin was also undetectable in patients with central
diabetes insipidus but elevated in patients with congenital
nephrogenic diabetes insipidus (12.9 1.6; 15.4 2.7; 14.2
2.3; 13.4 1.9; 14.6 1.4; 18.0 2.5 pg/mi, at 0, 60, 120, 180,
210 and 240 minutes). Platelet-fraction arginine-vasopres sin
concentrations did not change during the first 210 minutes of the
dehydration and hypertonic saline procedure. However, a
significant increase was measured at 240 minutes, probably
corresponding to additional "binding" to or incorporation of
vasopressin into the platelets or both in response to higher
circulating concentrations of AVP.
Discussion
The present studies are the first demonstration that platelet
vasopressin receptors are normal in patients with congenital
nephrogenic diabetes insipidus. Normal V1 receptor-effector
696 Bichet ci a!: Congenital nephrogenic diabetes insipidus
A Normal subjects
—20
—10
B Congenital nephrogenic Dl
120
100
80
20
0
—20
—10 —9 —8 —] —6 —5 —4
C Autosomal dominant central Dl
120
100
80
60
40
Log FAVP], M
Fig. 1. Platelet aggregation induced by increasing concentrations of
AVP in the three groups of subjects. Values obtained for individual
subjects are represented in each group. Results are expressed as the %
of maximal change in light transmittance after the addition of AVP (A
Max).
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Fig. 2. Platelet aggregation with increasing concentrations of argi-
nine-vasopressin (A VP) and its inhibition by increasing concentrations
of the speqfic vascular antagonist [13-mercapto-p, f3, cyclopentamethyl-
enepropionyl, O,Me, Tyr2,Arg8]-vasopressin in the three groups of sub-jects. Results are expressed as the % of maximal change in light
transmittance (A Max). Each point represents the mean SEM of4 to
6 experiments. Symbols are: AVP alone: normal subjects (•), CNDI(•), ADCDI (A); (V) AVP + antagonist 5 x 10 M; (0) AVP +
antagonist 1 x 10_8 M; () AVP + antagonist 2.5 x 108 M; (0) AVP
+ antagonist 5 x 10_s M. Error bars are contained within the symbol
when not visible.
congenital nephrogenic diabetes insipidus infused with vaso-
pressin. We did not repeat these experiments since pharmaco-
logical concentrations of AVP are needed to obtain a minimal
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responsiveness is in contrast with the abnormal renal and
extrarenal V2 receptor responses previously demonstrated in
the same subjects studied in our laboratory t4, 5]. Previous
indirect examination of V1 vascular responses in patients with
congenital nephrogenic diabetes insipidus have been limited to
single case reports. Orr and Filipich [11] obtained a 6 mm Hg
increase in mean arterial pressure in a male patient with
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Fig. 3. Plasma arginine-vasopressin concentrations (open bars) and
platelet-fraction arginine-vasopressin concentrations (hatched bars) in
normal subjects, in patients with congenital nephrogenic diabetes
insipidus (CNDI) and in patients with autosomal-dominant central
diabetes insipidus (ADCDI). Asterisks indicate significant differences
as compared to the two other groups.
increase in mean arterial blood pressure in normal individuals.
For example, Mohring et al [20] demonstrated in three human
volunteers with intact cardiovascular reflexes, that plasma AVP
concentration has to be increased to 500 pg/ml to achieve a 5 to
7 mm Hg increase in mean arterial blood pressure. Similar
results were obtained by Floras et al [211 in 12 normal subjects
infused with AVP: plasma concentrations of AVP were raised
to 320 68 pg/mI, but only modest (+6 mm Hg) and transient
increases in mean arterial blood pressure were observed. It is
notable that AVP also does not cause a rise in arterial blood
pressure when given intravenously to conscious animals with
an intact nervous system [221.
To study the vasoconstrictive properties of AVP, we elected
to examine the platelet vasopressin receptors and the platelet
aggregation induced by AVP. Pharmacological studies using
discriminating vasopressin analogues have indicated that hu-
man blood platelets have V1-receptors on their surface mem-
brane [14, 23, 24] and that the addition of AVP to human
platelets causes an increase in the turnover of phosphoinosi-
tides [251, a rise in cytoplasmic free calcium, and a shape
change reaction and aggregation [26, 271. Platelet aggregation
induced by vasopressin is potently inhibited by the V1 antago-
nists ([p-mercapto - f3,f3,cyclopentamethylenepropionyl,O -Me,
Tyr2,Arg8]vasopressin [281 and [1 -desamino,(4-valine,8-D-argi-
nine)]vasopressin [28]. In contrast, l-desamino[8-D-arginine]
vasopressin, a selective V2 agonist, fails to induce aggregation
of human platelets [29].
Platelet vasopressin receptors, platelet aggregative character-
istics and platelet-fraction AVP concentrations were similar in
normal subjects and in patients with congenital nephrogenic
diabetes insipidus. However, in patients with autosomal-domi-
nant central diabetes insipidus the number of receptors was
increased. In these patients, polyuric and polydipsic symptoms
were present since their first year of life, plasma vasopressin
concentrations were undetectable during dehydration and hy-
pertonic saline infusion. It is possible that the platelet receptors
are up-regulated by the undetectable concentrations of plasma
AVP in these patients. Vittet, Launay and Chevillard [30] have
suggested that the up-regulation could occur at the platelet
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Fig. 4. Plasma sodium concentration and plasma and platelet-fraction
arginine-vasopressin measurements obtained during dehydration and
hypertonic saline infusion in 3 male patients with congenital nephro-
genic diabetes insipidus and in 7 patients with autosomal-dominant
central diabetes insipidus. Symbols are: (El) plasma AVP; (U) platelet
AVP. Asterisks indicate significant differences (Dunnett) from baseline
values. Patients with autosomal dominant central diabetes insipidus had
undetectable (<0.5 pg/mi) plasma and platelet-fraction arginine-vaso-
pressin concentrations.
precursor stage. These authors examined the effects of dehy-
dration and overhydration on maximal platelet AVP-binding
capacity and AVP-induced platelet aggregation in human vol-
unteers. They found no correlation in the same individuals
between the state of hydration, the platelet maximal binding
capacity and the platelet aggregation responses. However, a
significant inverse correlation between plasma AVP concentra-
tions and the maximum binding capacity was demonstrated
among different individuals. These authors concluded that
homologous regulation of platelet AVP receptors by AVP does
not occur in vivo over the time investigated, at least within the
physiological range of AVP, but that a regulation at the platelet
precursor stage was highly probable [301.
We were unable to demonstrate differences in platelet aggre-
gation patterns among the three groups. Two explanations
could be offered. First the variability of the method used and
the limited number of patients included in each group may not
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permit detection of differences (lack of "power"), Another
possibility is that the post-receptor amplification phenomenon
involved in the aggregation of platelets makes differences
between groups unlikely.
The Kd (1 nM) of vasopressin binding to platelets has been
found to be similar to the EC50 (1.2 nM) of vasopressin for
inhibition of adenylate cyclase on platelet membranes [291 but
lower than the BC50 of vasopressin to induce platelet shape
change (7 flM) [311, aggregation (28 nM) [231, Ca2 mobilization
(50 nM) [321, and phosphatidic acid formation (30 nM) [32].
These differences could be explained by different experimental
conditions under which binding studies and functional studies
were carried out. Platelet metabolism and function, in contrast
with binding of hormones to their surface receptors, may be
very sensitive to in vitro manipulations. The isolation of plate-
lets may change the post-receptor effect of vasopressin on
platelets but have no effect on vasopressin binding.
The present measurements of platelet-fraction arginine-vaso-
pressin in patients with congenital nephrogenic diabetes insip-
idus and in patients with autosomal-central diabetes insipidus
complete a series of platelet-fraction arginine-vasopressin mea-
surements which started in our laboratory with measurements
in normal subjects [14] and in patients with congestive heart
failure [171. In patients with congenital nephrogenic diabetes
insipidus, platelet-fraction arginine-vasopressin increased sig-
nificantly during the periods of dehydration and hypertonic
saline infusion only at 240 minutes, that is, at a time when
plasma arginine-vasopressin release was maximally stimulated.
This result is in accordance with our previous results [14] and
those of others [30, 33] which demonstrated that platelet
arginine-vasopressin remained at less than 5 to 7 pg/mI during
short periods of dehydration. In contrast, the administration of
pharmacological doses of vasopressin to patients with central
diabetes insipidus was accompanied by plasma concentrations
of arginine-vasopressin larger than 10 pg/mI, and platelet-
fraction arginine-vasopressin concentrations close to 10 pg/mI
[141.
We previously suggested that platelet-fraction arginine-vaso-
pressin was an index of the long-term stimulation of AVP
release (osmotic and non-osmotic) [14, 17]. The observations
that platelet-fraction AVP concentrations are undetectable in
patients with central diabetes insipidus whereas high concen-
trations are present in patients with congenital nephrogenic
diabetes insipidus are in line with our initial observations. In
our present findings, there was no relationship between platelet
AVP content and the maximal binding capacity of vasopressin
to platelets. Platelet AVP content then more likely reflects the
long-term stimulation of AVP release rather than specific bind-
ing to platelet receptors.
Platelet arginine-vasopressin measurements were clearly dif-
ferent in patients with central diabetes insipidus and in patients
with nephrogenic diabetes insipidus, even when blood sampling
was done under conditions of free access to water (Fig. 3). The
measurement of arginine-vasopressin in platelet-rich plasma
could thus be useful in the evaluation of polyuric states. The
diagnosis of non-osmotic polyuria is difficult in infants due to
the necessity of dehydration and multiple blood sampling pro-
cedures. Platelet-fraction arginine-vasopressin measurements
could be, in these conditions, a useful addition to the classical
recommendations of Robertson [341.
Our observations in patients with hereditary disorders of
water metabolism are of particular importance in the search for
the molecular defect responsible for these disorders. It has
recently become possible to follow the inheritance of the
congenital nephrogenic diabetes insipidus gene with polymor-
phic DNA probes [35—39]. By analogy with the recent triumphs
of the "reverse" genetics [40, 41], genetic studies could lead to
the identification of the gene involved in congenital nephrogenic
diabetes insipidus. The protein coded by this gene is specific for
the vasopressin V2 receptor response since it apparently is not
involved in intact V1 responses.
In summary, we examined platelet vasopressin receptors in
normal subjects, patients with central diabetes insipidus and
patients with congenital nephrogenic diabetes insipidus. We
observed normal binding and aggregative characteristics in
patients with congenital nephrogenic diabetes insipidus but an
increasing number of receptors in patients with central diabetes
insipidus. Platelet-fraction vasopressin concentrations were
high in patients with nephrogenic but undetectable in patients
with central diabetes insipidus. These results demonstrate that
the V1 platelet-vasopressin receptors are normal in patients
with congenital nephrogenic diabetes insipidus and confirm the
potential diagnostic importance of platelet-fraction arginine-
vasopressin measurements.
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